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Abstract
The genes encoding nuclear receptors comprise multiple 59untranslated exons, which give rise to several transcripts
encoding the same protein, allowing tissue-specific regulation of expression. Both human and mouse peroxisome
proliferator activated receptor (PPAR) a genes have multiple promoters, although their function is unknown. Here we have
characterised the rat PPARa promoter region and have identified three alternative PPARa transcripts, which have different
transcription start sites owing to the utilisation of distinct first exons. Moreover these alternative PPARa transcripts were
differentially expressed between adipose tissue and liver. We show that while the major adipose (P1) and liver (P2)
transcripts were both induced by dexamethasone, they were differentially regulated by the PPARa agonist, clofibric acid,
and leptin. Leptin had no effect on the adipose-specific P1 transcript, but induced liver-specific P2 promoter activity via a
STAT3/Sp1 mechanism. Moreover in Wistar rats, leptin treatment between postnatal day 3–13 led to an increase in P2 but
not P1 transcription in adipose tissue which was sustained into adulthood. This suggests that the expression of the
alternative PPARa transcripts are in part programmed by early life exposure to leptin leading to persistent change in
adipose tissue fatty acid metabolism through specific activation of a quiescent PPARa promoter. Such complexity in the
regulation of PPARa may allow the expression of PPARa to be finely regulated in response to environmental factors.
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Introduction
PPARa is a ligand-activated transcription factor, which belongs
to the nuclear hormone receptor superfamily [1,2]. PPARa plays a
major role in lipid homeostasis by regulating the transcription of
genes that encode the rate limiting enzymes in b oxidation, namely
carnitine palmitoyl transferase (CPT-1) and acyl CoA oxidase
(AOX)[3–5]. Targeted disruption of the PPARa gene in mice
leads to lipid accumulation in the liver, impaired insulin secretion
during fasting [6], increased adipose tissue mass and an increased
incidence of liver tumours [7,8]. Consistent with these findings,
agonists of PPARa have been used as effective hypolipidemic
drugs [9].
PPARa is mainly expressed in tissues with high rates of fatty
acid b oxidation such as liver, skeletal muscle, brown fat, heart,
and kidneys[10;11]. Its expression is known to be regulated
through the action of glucocorticoids [12], by HNF4, a major
regulator of gluconeogenesis, [13], and by PPARa itself [14,15].
Adenoviral induced hyperleptinemia, which causes a rapid loss of
body fat without a rise in plasma FFA or ketone bodies, has also
been shown to increase the expression of PPARa and its target
genes in white adipose tissue, a tissue where PPARa is not
normally expressed. Conversely, the expression of PPARc2 and its
associated genes involved in lipogenesis were reduced. However,
the effects of hyperleptinemia were transient and two months after
the concentration of leptin returned to normal, levels of PPARa
expression decreased in adipose tissue and fat levels were regained
[16–19]. This transient transformation of adipocytes from fat
storing cells into fat burning cells via the induction of PPARa
expression might suggest a novel approach for the treatment of
obesity and a potential target for weight reduction.
There is also evidence that PPARa gene transcription can be
programmed by environmental factors in early life [20]. For
example the expression of PPARa is increased in the liver of
offspring born to dams fed a protein restricted (PR) diet during
pregnancy. The increase in PPARa expression in the PR offspring
is accompanied by the increased expression of its target gene acyl-
CoA oxidase (AOX) and an increase in levels of fatty acid beta-
oxidation[20 21]. In contrast, a 70% global dietary restriction
during pregnancy induces a persistent decrease in PPARa
expression in the liver of the adult offspring suggesting that
different nutritional challenges during pregnancy induce distinct
long term effects on PPARa expression [22]. In addition, there is
evidence in the rat that PPARa expression is programmed by
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neonatal leptin exposure [22,23]. Neonatal leptin administration
which reverses the phenotypic effects of maternal under nutrition
by slowing neonatal weight gain, normalizing caloric intake and
locomotor activity, induced a persistent increase in hepatic PPARa
expression [22]. This is in contrast to the effects of hyperleptinae-
mia on PPARa expression in adipose tissue of adult rats where the
increase in PPARa expression was not sustained after leptin
administration was discontinued, suggesting that the timing of
leptin exposure may determine the longevity of the response.
To date, little is known about of the molecular factors that
mediate the tissue-specific regulation of PPARa, or its regulation
by perinatal factors or leptin. The genes encoding nuclear
receptors frequently comprise multiple 59untranslated exons giving
rise to transcripts, which are expressed differentially between
tissues. The human [24], mouse [25], and rat [26] PPARa gene
promoters have only been partially characterised. The human
PPARa gene is composed of 12 exons and generates 7 mRNA
variants with different 59UTR exons. The 59UTR of the human
PPARa gene contains 7 exons (exons A, 1A, B, 1B, 2A, 2B and the
59end of exon 3), while the coding exons are derived from the
remainder of exon 3 and exons 4–8[27–29]. The mouse PPARa
gene is composed of 9 exons and generates 3 transcripts. Four
exons comprise the 59UTR (exon 1a, 1b, 2 and the 59end of exon
3), the coding exons, like the human orthologue, are composed of
the 39end of exon 3 and exons 4–8 [25]. The rat PPARa gene is
comprised of 8 exons with 1 transcript reported to date. Three
exons comprise the 59UTR exons, exon 1, 2 and the 59 portion of
exon 3 [26]. Because of the complexities of the human and mouse
genes, we hypothesised that the rat PPARa gene might also exhibit
heterogeneity in the 59UTR leading to the synthesis of multiple
transcripts. We have, therefore, characterised the promoter
structure of the rat PPARa gene, and determined the pattern of
expression between tissues and the extent to which alternative
transcripts are differentially regulated by leptin. We show that rat
PPARa gene gives rise to three PPARa mRNA variants, which
differ from each other at the 59 end owing to the presence of
unique first exons. The alternative PPARa transcripts were
differentially expressed between adipose tissue and liver. We show
that while the major adipose (P1) and liver (P2) transcripts were
both induced by dexamethasone, they were differentially regulated
by clofibric acid and leptin. Leptin had no effect on the adipose
specific P1 transcript, but induced the liver specific P2 promoter
activity via a STAT3/Sp1 mechanism. Moreover, consistent with
leptin regulation of transcription from the P2 promoter in vitro,
neonatal leptin treatment led to a persistent increase in transcrip-
tion from the P2 promoter and not the P1 promoter in adipose
tissue. Such 59 heterogeneity and complexity of regulation of
PPARa may provide additional layers of control by which PPARa
expression can be intricately regulated in response to hormones
and early life environment in a tissue specific manner.
Materials and Methods
Ethics Statement
All animal work was approved by the Animal Ethics Committee
of the University of Auckland (Approval N856) and complied with
the New Zealand Code of Ethical Conduct for the care and use of
animals for scientific purposes (Animal Welfare Act, 1999).
Animal Methods
A detailed description of the study design has been published
previously [23]. Briefly, virgin Wistar rats (age 10065 days) were
time-mated and fed a standard rat chow fed ad libitum throughout
gestation. Litter size was adjusted to 8 pups at birth to ensure
standardised nutrition until weaning. At postnatal day 3, female
pups were randomized to receive either saline or recombinant rat
leptin (rat leptin from Protein Laboratories, Rehovot, Israel)
(2.5 mg/g/day) for 10 days by subcutaneous injection (n= 16 per
group). Dams were fed ad libitum until offspring were weaned on
day 22. Saline or leptin-treated offspring were weaned onto
standard rat chow. This produced 8 groups of female rats (n = 8
per group). On postnatal day 170, rats were fasted overnight, and
killed by halothane anaesthesia followed by decapitation. Liver
and retroperitoneal adipose tissue was removed immediately,
frozen in liquid nitrogen and stored at 280uC.
Analysis of mRNA Expression
Total PPARa, P1 and P2 PPARa, AOX and carnitine
palmitoyltransferase (CPT)-1 mRNA concentrations were deter-
mined by real time RTPCR [30,31]. Briefly, total RNA was
isolated from cells using TRIZOL reagent (InVitrogen, Paisley,
Scotland, UK), and 1 mg was used as a template to prepare cDNA
using 100 U Moloney-Murine Leukemia Virus reverse transcrip-
tase. cDNA was amplified using real time PCR primers specific to
total PPARa, P1 and P2 transcripts, AOX and CPT-1 (Table 1).
The reaction was performed in a total volume of 25 ml with
SYBRH Green Jumpstart Ready Mix (Sigma, Poole, Dorset, UK)
as described by the manufacturer. Samples were analyzed in
duplicate and Ct values were normalised to ribosomal 18S RNA
using the DDCt method [30].
59 RNA Ligase Mediated Rapid Amplification of cDNA
Ends (59 RLM RACE)
RNA was amplified using a 59 RNA Ligase Mediated Rapid
Amplification of cDNA Ends (RLM RACE) kit (Ambion)
according to manufacturer’s instructions. Briefly, 10 mg of total
RNA from liver and adipose tissue was incubated with calf
intestinal alkaline phosphatase to remove free 59 phosphates, the
59 CAP structure was then removed from the RNA with tobacco
acid pyrophosphatase (TAP) and the TAP treated RNA ligated to
the 59 RACE adapter and reverse transcribed into cDNA using
random hexamers. To amplify the 59 region of PPARa mRNA,
generated from the 59RLM RACE, nested gene specific reverse
primers for PPARa were designed (inner primer 59 TGACT-
GAGGAGGGGCTGGAA 39; outer gene specific primer 59
AGCCTTCACATGCGTGGACT 3) and used with the nested
forward 59 RACE adaptor primers provided by the kit. Cycling
conditions for both outer and nested PCR were initial denatur-
ation of 94uC 3 minutes, followed by 35 cycles of 94uC 30 s,
anneal at 60uC 30 sec, and extension at 72uC 1 minute 30 sec.
Resulting PCR products were purified, cloned into pGem T-Easy
(Promega) and sequenced. The sequence of the transcripts P1–3
was confirmed by sequencing multiple clones from liver and
adipose tissue.
DNA Cloning
100 ng rat genomic DNA was used as a template for PCR
amplification with primers designed to amplify 1–1.5 Kb of
upstream sequence from the transcription start site of the P1, P2
and P3 promoters (P1 and P2 forward primer: 59ATGAGCT-
CAGCAGCGTCCTGAGGCGTT 39; P1 reverse primer 59
ATAAGCTTACCTGAGGCTGCGCTCCG 39; P2 reverse
primer 59 ATAA.
GCTTGTGCCCTTCCTAGCGTGT 39; P3 forward: 59
ATAAGCTTGGAGTCTTCCTTCTGGTT 39; P3 reverse 59
ATACTCGAGTCTGCGTGGGTGTCTAAT 39). All primers
contained either a SacI or XhoI restriction site at the 59 end of the
Regulation of PPARa by Leptin
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forward primer, and a HindIII restriction site at the 59 end of the
reverse primer to allow cloning of PCR fragments into the pGL3
Basic reporter vector (Promega). Cycling conditions for PCR were
as follows; initial denaturation of 94uC 2 minutes, followed by 40
cycles of 95uC 45 s, anneal at a 60uC 45 sec, and extension at
72uC 5 minutes. Resulting PCR products were gel extracted,
cloned into the pGL3 Basic reporter vector (Promega) and
sequenced to confirm the presence of the insert. The Quik change
method of mutagenesis (Stratagene) was used to create a P2
promoter construct with a mutated Sp1 site. Two complementary
primers were designed using the QuikChangeH Primer Design
Program (Stratagene, Texas, USA) to change the Sp1 consensus
sequence GGGCGG to an EcoR1 restriction site GAATTC
(Forward primer 59 GCCTCAGGTGCCCAGGAATTC-
GAGGGCACGCGCGAGG 39 and reverse complement 59
CCTCGCGCGTGCCCTCGAATTCCTGGGCACCT-
GAGGC 39). The primers (0.4 mM) were then annealed to 30 ng
P2- pGL3 DNA and extended using Pfu polymerase. Cycling
conditions for PCR were as follows; initial denaturation of 95uC 2
minutes, followed by 18 cycles of 95uC 30 s, anneal at a 60uC
1 min, and extension at 72uC 4 minutes, followed by a final
extension at 72uC for 5 minutes. Resulting PCR products were
digested with the restriction enzyme DpnI at 37uC for 1 hour and
the product transformed into DH5a E.Coli. Clones were cut with
EcoR1 and sequenced to confirm the presence of the mutation.
Cell Culture and Transfections
The human hepatoma cell line HepG2 (ECACC- Sigma
Aldrich) was cultured in DMEM supplemented with 10% fetal
bovine serum, 2 mM glutamine, 10 u/ml penicillin and 100 ug/
ml streptomycin. HepG2 cells were transfected using calcium
phosphate [31,32], clofibric acid, dexamethasone, the Stat3
inhibitor PpYLKTK-mts and leptin were added immediately
after transfection at the stated concentrations and luciferase
activity measured 24 hrs later using the Luciferase Assay System
(Promega). All transfections were performed in triplicate and
values are expressed as luciferase activity per mg of protein.
Statistical Analysis
Statistical comparisons of mRNA expression and methylation
levels between treatments relative to the untreated control were
carried out using a Students unpaired t test. Statistical compar-
isons of luciferase activity levels between promoter constructs and
treatments were determined by ANOVA followed by Bonferoni’s
post hoc analysis. All values are plotted as the mean 6SEM.
Results
59RACE Analysis Identifies Distinct Tissue Specific
59leader Sequences in Rat PPARa mRNA
To investigate tissue specific 59heterogeneity of rat PPARa
mRNA, 59RLM RACE PCR analysis was conducted on total
RNA from adipose and liver tissue from adult Wistar rats. 59RLM
RACE revealed 2 different sized PCR products from the liver
(723 bp and 463 bp) but only 1 from adipose tissue (465 bp)
(Figure. 1A). The PCR products were cloned into the pGEM T-
easy vector and the resulting clones sequenced and compared to
the published genomic sequence of rat PPARa (Ensemble gene ID
ENSRNOG00000021463) to identify the genomic location of the
exons. The 3 transcripts differed from each other at the 59 end,
and comparisons to the genomic sequence showed that they had
different transcription start sites owing to the presence of unique
first exons. The PPARa transcripts were subsequently termed P1–
3 and a schematic diagram indicating the genomic location of the
PPARa 59UTR exons and the organisation of the alternative
59UTRs is shown in Figure 1b.
Five exons were found to encode the PPARa 59UTR covering a
genomic region of 42010 bps. Exons were named according to
their genomic location. Exons 1A and 2A were novel, one exon
was a modified version of exon 1 (now termed 1B), and the
remainder were exactly as identified by Ensembl (exons 2 and 3).
The 59UTR of the adipose specific transcript (P1) is encoded by
exons 1A, 2 and 3. The transcription start site for this transcript is
257 bp upstream of the Ensembl published start site (http://www.
ensembl.org/index.html), and gave rise to a distinct unique first
exon of 60 bp termed exon 1A. The liver specific transcripts were
termed P2 and P3. P2 comprises exon 1B, 2 and 3. Exon 1B
(previously exon 1) is 67 bp longer than the original exon 1 at the
59 end resulting in a 318 bp exon. The P3 transcript contains exon
2A which is a 145 bp novel exon located several Kb downstream
from exon 2, and has been termed exon 2A. This exon is spliced
directly onto Ensembl exon 3, and is the only transcript that does
not contain exon 2 (Figure.1c). All these exons conform to the
GT:AG splice site rule (Table 2). Comparison of the rat, mouse
and human PPARa 59UTR’s revealed that the previously
unidentified exon 1A, found in the rat 59UTR was homologous
to the mouse exon 1A and human exon A. The 59 end of this exon
is longer in the human and mouse corresponding exons, but all
share the same 39 exon boundary. Exon 1B in rat is longer at the
59end than previously reported making it more homologous with
the mouse and human corresponding exons. Rat exon 2A
identified by 59RACE had no corresponding exon in the mouse
59UTR but was present in the human 59UTR. (Figure 1d).
Table 1. Primer sequences used in the measurements of mRNA expression by real time RT PCR.




PPARa P1 ATGAGCTCAGCAGCGTCCTGAGGCGTT ATAAGCTTACCTGAGGCTGCGCTCCG
PPARa P2 ATGAGCTCAGCAGCGTCCTGAGGCGTT ATAAGCTTGTGCCCTTCCTAGCGTGT
18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGTAGCG
PPARa, peroxisomal proliferator-activated receptor-a; CPT-1, carnitine:palmitoyl transferase-1; AOX, acyl-CoA oxidase;.
doi:10.1371/journal.pone.0067483.t001
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The P2 Promoter has Highest Activity in Liver HepG2
Cells
To investigate whether the alternative PPARa exons are
associated with promoter activity, the 59 region immediately
upstream of the P1, P2 and P3 transcription start sites (from
approx 21.5 kb to +50 bp) were cloned into the reporter vector
pGl3basic and transfected into HepG2 cells. This resulted in two
partially overlapping promoter regions for P1 and P2 and a
distinct downstream promoter for P3 (Figure. 2a). Both P1 and P2
promoters were active in HepG2 cells with P2 having the highest
Figure 1. Tissue specific 59 heterogeneity of PPARa transcripts. A) 59 RLM RACE PCR indicates 2 major PPARa transcripts in liver and one in
adipose. M, DNA ladder; NTC, no template control; +C, RACE positive control; -C, negative control; -C, -TAP control; liver, liver cDNA; adipose, adipose
cDNA; M, DNA ladder. B) A schematic diagram showing the genomic organisation of the rat PPARa gene. Location of PPARa 59UTR exons on the
genomic sequence are shown (non-coding exons, black; coding exons, white and the updated exons, grey). All exon positions are indicated relative
to the Ensembl transcription start site. Ensembl exon 3 which contains the translation ATG start codon is present in all transcripts. C) Diagram
showing the adipose specific transcript (P1) and liver specific transcripts (P2 and P3). D) Comparison of the Rat PPARa 59UTR with the 59UTR of the
human and mouse PPARa genes. Non-coding 59UTR exons are shown in black, coding exons in white and newly identified non coding exons in grey.
doi:10.1371/journal.pone.0067483.g001
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promoter activity. The P3 promoter region showed very low levels
of activity, similar to that of the promoter-less pGL3 Basic vector
(Figure 2b).
To determine whether the individual PPARa promoters are
differentially regulated, the PPARa promoter-pGL3 luciferase
reporter constructs (P1, P2 and P3) were transfected into HepG2
cells and treated for 24 hrs with clofibric acid and dexamethasone
at a range of concentrations which have previously been reported
to induce PPARa expression [12,15]. Clofibric acid treatment
repressed P1 promoter activity at 60 mM (2.8 fold p= 0.001), but
induced P2 promoter activity at 80 mM (3.19 fold p= 0.001) and
100 mM (5.7 fold p= 0.001)(Figure. 2C). Both P1 and P2 promoter
activity was increased in the presence of dexamethasone. A
significant increase in P1 promoter activity at both 1 mM
dexamethasone (2.2 fold p= 0.01) and 10 mM dexamethasone
(3.22 fold p= 0.001) was observed. With P2 a significant rise in
promoter activity was observed with 10 mM dexamethasone (2
fold p= 0.001)(Figure. 2D). There was no effect of either
dexamethasone or clofibric acid on P3 promoter activity.
Leptin Treatment Induces Transcription from the P2 but
not the P1 or P3 Promoter
To determine whether leptin could induce transcription from
the alternative PPARa promoters, HepG2 cells were transfected
with the P1, P2 and P3 promoter constructs and treated with
increasing concentrations of leptin for 24 hrs. We found that P2
promoter activity was significantly increased in the presence of
500 ng/ml and 1000 ng/ml leptin. In contrast, leptin had no
effect on either P1 or P3 promoter activity (Figure. 3a). As leptin
has been shown to modulate transcription through a STAT3
signalling pathway [33] we used the highly selective STAT3
inhibitor (PpYLKTK-mts) [34] to test the role of STAT3 in the
induction of P2 transcription by leptin. We found that while the
STAT3 inhibitor had no effect on P1 promoter activity, the
STAT3 inhibitor blocked leptin activation of P2 promoter activity
at 10 nM (Figure. 3b).
Leptin modulation of transcription via STAT3 has been shown
to occur either directly through the binding of STAT3 to its
response element in the promoter of a gene or indirectly through a
STAT3/Sp1 co-operative mechanism [35]. As the PPARa P2
promoter lacks a STAT3 binding site but contains a Sp1 site which
is located within the region unique to the P2 promoter, we next
investigated whether this Sp1 site was essential for leptin induction
of P2 transcription. The Sp1 site was mutated from GGCGGG to
the EcoR1 recognition site GAATTC. The wild type and mutated
promoter constructs were then transfected into HepG2 cells and
treated with 1000 ng/ml of leptin for 24 hrs. We found that the P2
promoter containing the mutated Sp1 site no longer responded to
leptin, suggesting that this Sp1 site is essential for leptin activation
of PPARa transcription (Figure.3C).
Differential Regulation of Alternative PPARa Transcripts
by Neonatal Leptin
As there is evidence that hepatic PPARa gene transcription can
be programmed by environmental factors in early life including
leptin, we next investigated whether neonatal leptin treatment
induced a persistent increase in PPARa expression in adipose
tissue and whether the P1 and P2 transcripts were differentially
affected. The expression of PPARa together with its target genes
AOX and CPT-1 were examined in adipose tissue from PN170
rats treated with either saline or leptin (2.5 mg/g/day) by
subcutaneous injection for 10 days from PN3-13. This dosage of
leptin was used, as similar levels have been reported previously to
induce leptin receptor signaling, alter neuropeptide expression
[36,37] and reverse the metabolic features induced by maternal
under nutrition. To analyze PPARa expression, primers were
designed to anneal to the coding region of PPARa, a region
common to all isoforms of PPARa, in order to measure total
PPARa transcript levels, and to the specific P1 and P2 transcripts.
Neonatal leptin administration led to an increase in total PPARa,
AOX and CPT-1 mRNA in adipose tissue from D170 old rats
compared to saline treated controls. However there was no effect
of leptin treatment on the expression of the P1 transcript
(Figure. 4b), while neonatal leptin treatment significantly increased
P2 specific transcripts in adipose tissue.
To determine whether this persistent increase in transcription
from the P2 promoter in response to neonatal leptin treatment was
due to altered DNA methylation, sodium bisulfite pyrosequencing
was performed using genomic DNA extracted from adipose tissue
from neonatal saline and leptin treated adult female rats. The
analysis of the region (2336 to2117 bp) immediately upstream of
the PPARa P2 transcription start site (TSS) which contains the
Sp1 response element in the P2 unique region showed that all
CpGs within this region had a methylation level of below 10%
regardless of treatment (Figure 5.), although differences in
methylation were observed between the leptin and saline treated
offspring at CpGs 7,11,12 and 17 (CpG 7 (2.6% to 1.2%,), CpG
11 (1.6% to 0.2% ), CpG 12 (2.85% to 0.73%) and CpG 17 (4.3%
to 1.8%,).
Discussion
The genomic organisation of the human and mouse PPARa
genes indicate that PPARa, like other nuclear receptors, contains
Table 2. Alternative PPARa 59UTR exon/intron junctions conform to the GT-AG splice site rule.
Transcript Exon (bp)
59 Donor Splice Site Consensus
59-gtaagt-39
39 Acceptor Splice Site Consensus
59-PyPyPyPyPyPyncag-39 Exon (bp)
Adipose P1 1A (60) CCTCAGgtgccc cgttctatagCCAAGA 2 (87)
2 (87) TCACAGgtaaga cctcctacagATTGGT 3 (247)
Liver P2 1B (318) GGCGAGgtaact cgttctatagCCAAGA 2 (87)
2 (87) TCACAGgtaaga cctcctacagATTGGT 3 (247)
Liver P3 2A (145) CTTCTGgtaggt cctcctacagATTGGT 3 (247)
59 (donor) and 39 (acceptor) intron splice site consensus sequences are indicated. The sequences at P1, P2 and P3 transcript exon/intron boundaries are shown. Splice
site sequences within introns are shown in lowercase; Exons are shown in capitals, and sizes of exons are given. All transcript exon boundaries conform to the GT-AG
splice site rule.
doi:10.1371/journal.pone.0067483.t002
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multiple 59UTR variants and promoter regions [27]. Previously
rat PPARa was not known to have any mRNA variants and only
three exons (exons 1, 2 and 3) were found to encode the 59 UTR.
In this study, 59 RACE analysis revealed three PPARa mRNA
variants, with 2 transcripts identified in liver (P2 and P3) and one
in adipose (P1). These transcripts differed from each other at the 59
end, and comparisons to the genomic sequence showed that they
had different transcription start sites owing to the presence of
unique first exons. Five exons were found to encode the PPARa
59UTR, Exons 1A and 2A were novel, one exon was a modified
version of exon 1 (now termed 1B), and the remainder were
exactly as identified previously [26]. The identification of the
additional 59UTR first exons in the rat PPARa promoter increases
the homology between the rat, mouse and human PPARa
promoter structures. For example, the 59 extended exon 1B in
the rat P2 transcript and the novel exon 1A in the rat P1 transcript
are both present in the human and mouse 59UTR. In addition, the
rat P1 and P2 PPARa transcripts are very similar with those
identified in the mouse, the rat P2 transcript being equivalent to
the mouse variant 1 and the newly identified rat P1 transcript
being similar to the mouse variant 2.
Since the 59 UTR can modulate RNA stability[38–40],
translation efficiencies [41,42] as well as subcellular localisation
[43,44], the use of alternative promoters to regulate the expression
of untranslated first exons may add a further layer of control to the
regulation of PPARa expression. For example, the presence of a
long 59UTR, high GC content, secondary structure, uATGs and
uORFs are all associated with reduced translational efficiency of
the main ORF [45]. The relatively high GC content of the 59UTR
was fairly consistent between the three PPARa alternative
transcripts, but the length of the 59UTR varied from 184 bp for
P3, to 444 bp for P2. This difference in length was reflected by
differences in the minimum free energies of the transcripts
calculated using Zucker RNA mfold 2.3 software which ranged
from 274.65 Kcal/mol for P1, 2169.75 Kcal/mol for P2 and
256.15 Kcal/mol for P3 [46]. Secondary structures within the
59UTR with values of less than 30 Kcal/mol can be melted by the
ribosome during the normal scanning process [47]. However, all
three PPARa transcripts contain hairpins with stabilities of greater
than this, indicating these transcripts may impede ribosomal
movement and may be subjected to translational regulation.
The P1 and P2 transcripts did not contain ATG initiation
codons in the sequence upstream of the previously reported ATG
codon suggesting that they possess the same open reading frame as
the previously reported transcript. The P3 transcript, however,
contains four uATGs, 3 have adequate Kozak consensus
sequences [47], but are followed by a termination codon.
However, one ATG is in frame with the downstream ATG, and
thus has the potential to produce a protein with a 30aa extended N
terminal. PPARc2 has an extended N terminal of 30aa and 28aa
in mice and humans, respectively, compared to the predominant
PPARc1 protein. Experiments have shown that the PPARc2 N
terminal extension comprises an N terminal ligand independent
activation domain that mediates 5–6 times the activation of
PPARc1 under ligand depleted conditions [48]. However, further
studies are needed to determine whether the PPARa P3 transcripts
contain a functional extended protein.
The analysis of the sequence upstream of the transcription start
sites of the P1, P2 and P3 sites revealed that the P1/P2 promoters
possess the characteristics of typical GC rich promoters common
to nuclear hormone receptors such as the absence of TATA
elements and the presence of CpG islands containing multiple Sp1
response elements. The P3 promoter, in contrast, did not contain
any CpG islands or Sp1 response elements. Moreover, unlike the
sequences upstream of the P1 and P2 TSS, which gave rise to high
levels of promoter activity in HepG2 cells, the sequence upstream
of the P3 start site was not active in HepG2 cells. This low activity
may indicate that important regulatory elements outside the region
cloned in this study are required for P3 expression or that the
promoter is inactive in the absence of stimulatory factors that are
not present in liver cell line HepG2.
It has been reported previously that PPARa transcription is
induced by CFA [15], dexamethasone [12] and leptin [49].
Interestingly, the response of the adipose specific (P1) and liver
specific (P2) promoters to these treatments differed. Both P1 and
P2 promoters were up-regulated by dexamethasone, suggesting
that glucocorticoids modulate PPARa expression through a
sequence shared by the P1 and P2 promoters. Previous
experiments have shown that GR can directly regulate PPARa
expression [50] although the precise sequence was not identified.
Matinspector analysis (www.genomatix.de) of the promoter region
of PPARa did not reveal any glucocorticoid response elements,
but a putative NF-1 binding site was identified in the sequence
shared by both P1 and P2. NF-1 is a transcription factor that has
been shown to mediate GR responsiveness [51]. In contrast, P1
and P2 promoters were differentially regulated by clofibric acid, a
PPARa agonist and leptin, suggesting that leptin and clofibric acid
mediate their effects through a sequence(s) that are unique to the
P2 promoter. Autoregulation of gene expression is commonly
found in nuclear receptors and ligands of PPARa have previously
been reported to activate PPARa expression at the transcriptional
level by binding to either a PPRE or DR1 motif [24], the latter of
which is present within the unique region of the P2 promoter.
Leptin has been suggested to regulate gene expression through the
activation of Stat3 via a JAK signalling pathway [52–54], or in a
promoter which lack a STAT3 response element, through a Stat3-
Sp1 co-operative mechanism whereby Stat3 phosphorylates Sp1
which, in turn, facilitates Sp1 binding to its response elements
[55]. The mechanism of leptin induction of P2 transcription
involved both Stat3 and an Sp1 response element present in the
sequence that is unique to the P2 promoter.
Leptin plays a critical role in maintaining energy balance
[56,57] and also has an emerging role in growth and development
[58]. Adipogenesis is associated with a marked elevation in serum
leptin concentration which occurs between 4 to 10 days after birth
in mice [59], while in rats, peak leptin concentration occurs at
about 10 days after birth [60]. This increase in leptin has been
shown to play a crucial neurotrophic role in the development of
projections from the arcuate nucleus of the hypothalamus, which
regulates food intake and adiposity [36,61]. Several reports
indicate that the neonatal leptin surge is disturbed in its timing
Figure 2. P1 and P2 promoters are active in HepG2 cells. A) Schematic diagram showing the relative locations of PPARa P1, P2 and P3 cloned
promoter regions and their positioning relative to Ensembl transcription start site and 59UTR exons. B) PPARa P1, P2 and P3 promoter constructs (P1,
P2 and P3 Prom 1 mg) and an empty control vector (pGL3Basic 1 mg) were transfected into HepG2 cells and promoter activity assessed 24 hrs later. C
and D) Regulation of PPARa promoter activity by clofibric acid and dexamethasone. P2 and P3 promoter constructs were transfected into HepG2 cells
and treated for 24 hrs with vehicle control or an increasing concentration of dexamethasone (0, 0.1, 1 or 10 mM) or clofibric acid (60, 80, 100 mM). All
values represent the mean of 6 independent experiments 6SEM.). Statistical comparisons of luciferase activity between treatments relative to the
untreated control were determined by ANOVA followed by Bonferroni post hoc analysis. (* p,0.05, ** p,0.001, *** p,0.001).
doi:10.1371/journal.pone.0067483.g002
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and/or magnitude by maternal undernutrition [61,62]. Moreover
neonatal leptin administration from PN3–13 has been shown to
reverse many of the features of metabolic programming induced
by maternal undernutrition by slowing neonatal weight gain,
normalizing caloric intake, locomotor activity, body weight and fat
mass in adult offspring of undernourished mothers fed a HF diet
[23]. The mechanism by which neonatal leptin treatment induces
persistent changes in the regulation of fat mass was presumed to
involve an effect on hypothalamic neurogenesis. Our findings
however show that neonatal leptin administration induces a
persistent increase in PPARa mRNA expression and its target
genes AOX and CPT-1 in adipose tissue, suggesting that leptin
may also have peripheral metabolic effects on adipose tissue. The
increase in PPARa mRNA is consistent with the previous reports
that hyperleptineamia induces PPARa expression in adipose
tissue. Although interestingly while a transient increase in PPARa
expression was observed in response to hyperleptinemia which
disappeared when levels of leptin returned to normal, neonatal
leptin treatment induced a stable increase in PPARa expression in
adipose tissue which persisted into adulthood. This difference in
the duration of the response to leptin may reflect the timing of the
exposure during the life-course, as there is now growing evidence
that early life exposures can induce long term effects on the
metabolism and physiology of the offspring via epigenetic
processes [63]. Consistent with the induction of P2, but not P1,
promoter activity in cell culture experiments, neonatal leptin
treatment differentially-regulated transcription from the PPARa
P1 and P2 promoters in adipose tissue by persistently inducing P2,
but not P1, transcription. A decrease in methylation at four CpGs
within the P2 promoter was seen in the neonatal leptin treated
compared to the saline treated animals. However given the low
levels of methylation in this region, it is unclear whether such
differences in methylation would mediate a switch in promoter
usage although there is precedent for differences in methylation at
low levels altering gene function [64].
In conclusion we show that the rat PPARa gene has multiple
transcripts, which are expressed in a tissue specific manner and are
differentially regulated by leptin. Moreover neonatal leptin
exposure induces a persistent change in adipose tissue gene
expression through specific activation of an otherwise quiescent
PPARa promoter. It is possible that leptin may have similar effects
in other species. For example, human PPARa also has multiple
promoters and hence it is possible that long term modulation of
PPARa activity, and hence lipid metabolism, by promoter
switching as a result of leptin exposure in early life may also
occur in humans. If the changes to gene expression in adipose
tissue reported in the present study were to occur in humans, it
may be expected that those who experience higher leptin exposure
Figure 3. Leptin activates the PPARa P2 Promoter in HepG2 Cells P1, P2 and P3 promoter constructs were transfected into HepG2
cells and treated for 24 hrs with a vehicle control or an increasing concentration of leptin (0,50, 500, 1000 ng/ml). B) P1 and P2
promoter constructs were transfected into HepG2 cells and treated for 24 hrs with leptin (1000 ng/ml) and an increasing concentration of the STAT3
inhibitor PpYLKTK-mts (0,1,10 nM). C) Mutation of the Sp1 site blocks leptin activation of P2 promoter activity. P2 (P2-pGL3) and P2 promoter
construct containing the mutated Sp1 response element (SP1M EcoRI-pGL3) was transfected into HepG2 cells and treated with leptin (1000 ng/ml)
for 24 hrs. All values represent the mean of 6 independent experiments 6SEM. Statistical comparisons of luciferase activity between treatments
relative to the untreated control were determined by ANOVA followed by Bonferroni post hoc analysis. (* p,0.05, ** p,0.001, *** p,0.001).
doi:10.1371/journal.pone.0067483.g003
Figure 4. Neonatal leptin treatment leads to a persistent increase in PPARa P2 transcription. A) Neonatal leptin treatment induces a
persistent increase in total PPARa transcripts, AOX and CPT-1 mRNA expression in retroperitoneal adipose. Values represent the mean6 SEM relative
to the saline treated control group. Statistical comparisons between the control (Con) and neonatal leptin treated (Leptin) groups were made using a
Students unpaired t test. B) The expression of the P2 but not the P1 PPARa transcript is significantly altered by neonatal leptin treatment. Values
represent the mean 6S EM relative to the saline treated control group. Statistical comparisons between the control (Con) and leptin treated (Leptin)
groups were made using Students unpaired t test. (* p,0.05, ** p,0.001, *** p,0.001).
doi:10.1371/journal.pone.0067483.g004
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in early life would have greater capacity to meet the metabolic
challenge of a high calorie diet after weaning, while a lower leptin
exposure would result in a reduced capacity to regulate fatty acid
deposition in adipose tissue. This may explain, at least in part, the
observation that low umbilical cord blood leptin levels are
associated with rapid postnatal weight gain [65]. One implication
is that leptin exposure during specific periods in development may
influence future risk of obesity.
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Figure 5. Pyrosequencing analysis of the PPARa promoter in adipose tissue of saline or leptin treated adult female rats. A) Schematic
diagram showing the location of the CpGs sequenced. All exon positions are indicated relative to the Ensembl transcription start site B)
Pyrosequencing analysis of CpGs within the PPARa promoter. Values represent mean methylation levels 6SEM (n= 8/group).Only CpG sites where a
significant difference in methylation between the saline and leptin treated groups are shown. Saline treated, black bars (C), leptin treated white bars
(L). Significant differences in DNA methylation between saline and leptin treated groups was determined using a Students unpaired t-test where
*p,0.05.
doi:10.1371/journal.pone.0067483.g005
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